Immunotherapy combo shows promise against early lung cancer
NCT ID NCT04015778
First seen May 21, 2026 · Last updated May 21, 2026
Summary
This study tests whether the immunotherapy drug nivolumab, alone or with chemotherapy, can shrink early-stage non-small cell lung cancer before surgery and help prevent it from coming back after. About 316 people with stage II or IIIA lung cancer that can be removed surgically are taking part. The goal is to see if this approach improves outcomes and to learn more about how the immune system responds.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Guangdong Lung Cancer Institute, Guangdong General Hospital, Guangdong Academy of Medical Sciences
Guangzhou, Guangdong, 510080, China
Conditions
Explore the condition pages connected to this study.